Gauthier J, Gazeau N, Hirayama AV, et al. Impact of CD19 CAR T-Cell Product Type on Outcomes in Relapsed or Refractory Aggressive B-NHL. Blood. 2022; (doi: 10.1182/blood.2021014497).
CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T cell product type independently affects both toxicity and efficacy in patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL), according to new research. The retrospective analysis, which sought to estimate the independent impact of the CAR T-cell product type on outcomes, included data from 129 patients with R/R aggressive B-NHL treated with cyclophosphamide and fludarabine lymphodepletion and then either axicabtagene ciloleucel, tisagenlecleucel, or the investigational product JCAR014. CAR T-cell product type still correlated with outcomes, even after adjusting for age, Hematopoietic Cell Transplantation-Comorbidity Index, lactate dehydrogenase (LDH), largest lesion diameter, and absolute lymphocyte count (ALC). Compared with axicabtagene ciloleucel, JCAR014 was associated with lower cytokine release syndrome severity. JCAR014 and tisagenlecleucel were also associated with lower immune effector cell-associated neurotoxicity syndrome severity and predicting lower odds of complete response (CR) compared with axicabtagene ciloleucel. Lower CR odds were independently correlated with higher preleukapheresis LDH, largest lesion diameter, and lower ALC.